Cargando…
Regulatory T Cells in Systemic Sclerosis
In recent years, accumulating evidence suggest that regulatory T cells (Tregs) are of paramount importance for the maintenance of immunological self-tolerance and immune homeostasis, even though they represent only about 5–10% of the peripheral CD4(+) T cells in humans. Their key role is indeed supp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196252/ https://www.ncbi.nlm.nih.gov/pubmed/30374354 http://dx.doi.org/10.3389/fimmu.2018.02356 |
_version_ | 1783364518207815680 |
---|---|
author | Frantz, Camelia Auffray, Cedric Avouac, Jerome Allanore, Yannick |
author_facet | Frantz, Camelia Auffray, Cedric Avouac, Jerome Allanore, Yannick |
author_sort | Frantz, Camelia |
collection | PubMed |
description | In recent years, accumulating evidence suggest that regulatory T cells (Tregs) are of paramount importance for the maintenance of immunological self-tolerance and immune homeostasis, even though they represent only about 5–10% of the peripheral CD4(+) T cells in humans. Their key role is indeed supported by the spontaneous development of autoimmune diseases after Tregs depletion in mice. Moreover, there is also a growing literature that investigates possible contribution of Tregs numbers and activity in various autoimmune diseases. The contribution of Tregs in autoimmune disease has opened up a new therapeutic avenue based on restoring a healthy balance between Tregs and effector T-cells, such as Treg-based cellular transfer or low-dose IL-2 modulation. These therapies hold the promise of modulating the immune system without immunosuppression, while several issues regarding efficacy and safety need to be addressed. Systemic sclerosis (SSc) is an orphan connective tissue disease characterized by extensive immune abnormalities but also microvascular injury and fibrosis. Recently, data about the presence and function of Tregs in the pathogenesis of SSc have emerged although they remain scarce so far. First, there is a general agreement in the medical literature with regard to the decreased functional ability of circulating Tregs in SSc. Second the quantification of Tregs in patients have led to contradictory results; although the majority of the studies report reduced frequencies, there are conversely some indications suggesting that in case of disease activity circulating Tregs may increase. This paradoxical situation could be the result of a compensatory, but inefficient, amplification of Tregs in the context of inflammation. Nevertheless, these results must be tempered with regards to the heterogeneity of the studies for the phenotyping of the patients and of the most importance for Tregs definition and activity markers. Therefore, taking into account the appealing developments of Tregs roles in autoimmune diseases, together with preliminary data published in SSc, there is growing interest in deciphering Tregs in SSc, both in humans and mice models, to clarify whether the promises obtained in other autoimmune diseases may also apply to SSc. |
format | Online Article Text |
id | pubmed-6196252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61962522018-10-29 Regulatory T Cells in Systemic Sclerosis Frantz, Camelia Auffray, Cedric Avouac, Jerome Allanore, Yannick Front Immunol Immunology In recent years, accumulating evidence suggest that regulatory T cells (Tregs) are of paramount importance for the maintenance of immunological self-tolerance and immune homeostasis, even though they represent only about 5–10% of the peripheral CD4(+) T cells in humans. Their key role is indeed supported by the spontaneous development of autoimmune diseases after Tregs depletion in mice. Moreover, there is also a growing literature that investigates possible contribution of Tregs numbers and activity in various autoimmune diseases. The contribution of Tregs in autoimmune disease has opened up a new therapeutic avenue based on restoring a healthy balance between Tregs and effector T-cells, such as Treg-based cellular transfer or low-dose IL-2 modulation. These therapies hold the promise of modulating the immune system without immunosuppression, while several issues regarding efficacy and safety need to be addressed. Systemic sclerosis (SSc) is an orphan connective tissue disease characterized by extensive immune abnormalities but also microvascular injury and fibrosis. Recently, data about the presence and function of Tregs in the pathogenesis of SSc have emerged although they remain scarce so far. First, there is a general agreement in the medical literature with regard to the decreased functional ability of circulating Tregs in SSc. Second the quantification of Tregs in patients have led to contradictory results; although the majority of the studies report reduced frequencies, there are conversely some indications suggesting that in case of disease activity circulating Tregs may increase. This paradoxical situation could be the result of a compensatory, but inefficient, amplification of Tregs in the context of inflammation. Nevertheless, these results must be tempered with regards to the heterogeneity of the studies for the phenotyping of the patients and of the most importance for Tregs definition and activity markers. Therefore, taking into account the appealing developments of Tregs roles in autoimmune diseases, together with preliminary data published in SSc, there is growing interest in deciphering Tregs in SSc, both in humans and mice models, to clarify whether the promises obtained in other autoimmune diseases may also apply to SSc. Frontiers Media S.A. 2018-10-15 /pmc/articles/PMC6196252/ /pubmed/30374354 http://dx.doi.org/10.3389/fimmu.2018.02356 Text en Copyright © 2018 Frantz, Auffray, Avouac and Allanore. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Frantz, Camelia Auffray, Cedric Avouac, Jerome Allanore, Yannick Regulatory T Cells in Systemic Sclerosis |
title | Regulatory T Cells in Systemic Sclerosis |
title_full | Regulatory T Cells in Systemic Sclerosis |
title_fullStr | Regulatory T Cells in Systemic Sclerosis |
title_full_unstemmed | Regulatory T Cells in Systemic Sclerosis |
title_short | Regulatory T Cells in Systemic Sclerosis |
title_sort | regulatory t cells in systemic sclerosis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196252/ https://www.ncbi.nlm.nih.gov/pubmed/30374354 http://dx.doi.org/10.3389/fimmu.2018.02356 |
work_keys_str_mv | AT frantzcamelia regulatorytcellsinsystemicsclerosis AT auffraycedric regulatorytcellsinsystemicsclerosis AT avouacjerome regulatorytcellsinsystemicsclerosis AT allanoreyannick regulatorytcellsinsystemicsclerosis |